NO20052229D0 - Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler - Google Patents

Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler

Info

Publication number
NO20052229D0
NO20052229D0 NO20052229A NO20052229A NO20052229D0 NO 20052229 D0 NO20052229 D0 NO 20052229D0 NO 20052229 A NO20052229 A NO 20052229A NO 20052229 A NO20052229 A NO 20052229A NO 20052229 D0 NO20052229 D0 NO 20052229D0
Authority
NO
Norway
Prior art keywords
immunostimulants
inflammatory
fatty alcohols
basic esters
esters
Prior art date
Application number
NO20052229A
Other languages
English (en)
Other versions
NO20052229L (no
Inventor
Gyorgy Toth
Irun R Cohen
Yaacov Herzig
Raanan Margalit
Jeffrey Sterling
Meir Shinitzky
Tivadar Tamas
Istvan Miskolczi
Ferenc Rantal
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20052229D0 publication Critical patent/NO20052229D0/no
Publication of NO20052229L publication Critical patent/NO20052229L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20052229A 2002-10-10 2005-05-09 Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler NO20052229L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41715702P 2002-10-10 2002-10-10
PCT/IL2003/000820 WO2004032824A2 (en) 2002-10-10 2003-10-09 Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents

Publications (2)

Publication Number Publication Date
NO20052229D0 true NO20052229D0 (no) 2005-05-09
NO20052229L NO20052229L (no) 2005-07-06

Family

ID=32093977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052229A NO20052229L (no) 2002-10-10 2005-05-09 Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler

Country Status (15)

Country Link
US (1) US8987263B2 (no)
EP (1) EP1551495A4 (no)
JP (1) JP2006502213A (no)
KR (1) KR20050071565A (no)
CN (1) CN100582085C (no)
AU (1) AU2003269466B2 (no)
BR (1) BR0314554A (no)
CA (1) CA2501318A1 (no)
IS (1) IS7781A (no)
MX (1) MXPA05003870A (no)
NO (1) NO20052229L (no)
NZ (1) NZ539106A (no)
RU (1) RU2337093C2 (no)
WO (1) WO2004032824A2 (no)
ZA (1) ZA200502613B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
EP2117301A4 (en) * 2007-02-26 2010-04-14 Yeda Res & Dev USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS
WO2009042440A1 (en) * 2007-09-28 2009-04-02 Cortria Corporation 1-methyl nicotinamide and derivatives for treatment of gastric injury
US8334240B2 (en) 2008-10-06 2012-12-18 Nalco Company Compositions and methods for inhibiting the agglomeration of hydrates in a process
US8105987B2 (en) 2008-10-06 2012-01-31 Nalco Company Corrosion inhibitors for an aqueous medium
US8329620B2 (en) * 2008-10-06 2012-12-11 Nalco Company Compositions and methods for inhibiting the agglomeration of hydrates
US8105988B2 (en) 2008-10-06 2012-01-31 Nalco Company Corrosion inhibitors for a fluid
US8921478B2 (en) 2008-10-17 2014-12-30 Nalco Company Method of controlling gas hydrates in fluid systems
US10392573B2 (en) 2008-10-17 2019-08-27 Ecolab Usa Inc. Method of controlling gas hydrates in fluid systems
US8288323B2 (en) 2009-03-02 2012-10-16 Nalco Company Compositions containing amide surfactants and methods for inhibiting the formation of hydrate agglomerates
US8618025B2 (en) 2010-12-16 2013-12-31 Nalco Company Composition and method for reducing hydrate agglomeration
US9505707B2 (en) 2010-12-22 2016-11-29 Nalco Company Composition and method for reducing hydrate agglomeration
US20150157588A1 (en) * 2012-07-05 2015-06-11 Yeda Research And Development Co., Ltd. Pharmaceutical Composition Comprising Amino-Phenyl-Acetic Acid Octadec-(Z)-9-enyl Ester and Use Thereof for Treating Tumors
US20140248371A1 (en) 2013-01-10 2014-09-04 Carmel-Haifa University Economic Corp. Ltd. Spalax fibroblast-derived anti-cancer agents
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) * 1909-10-07 2002-10-01 Medivir Ab Prodrugs
CH448122A (de) * 1963-10-14 1967-12-15 Hoffmann La Roche Verfahren zur Herstellung von Estern
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US3629111A (en) * 1970-10-02 1971-12-21 Olin Corp Hydraulic fluids containing novel inhibitor compositions
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
DE2234399A1 (de) * 1972-07-17 1974-01-31 Thomae Gmbh Dr K Hautschutzmittel
NO761120L (no) * 1975-04-07 1976-10-08 Ici Ltd
FR2383662A1 (fr) * 1977-03-15 1978-10-13 Cassenne Lab Sa Nouvelles compositions a usage cosmetique
FR2420545A1 (fr) 1978-03-20 1979-10-19 Anvar Nouveaux esters de l'acide n-acetyl-muramyl-aminoacyl-glutamique ou des derives de substitution de celui-ci a proprietes anti-infectieuses et/ou d'adjuvants immunologiques
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
EP0064366A1 (en) * 1981-04-29 1982-11-10 Beecham Group Plc Pharmaceutical compositions
JPS5892607A (ja) * 1981-11-26 1983-06-02 Lion Corp 毛髪化粧料
DE3482551D1 (de) * 1983-10-26 1990-07-26 Kanebo Ltd Proteinhaltiges emulgiermittel, dessen herstellung und dieses enthaltende emulgierte kosmetische zusammensetzung.
US4749694A (en) * 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
JPS61103826A (ja) 1984-10-25 1986-05-22 Kao Corp 抗炎症剤
JPS61226977A (ja) * 1985-03-30 1986-10-08 Toshiba Corp 発光素子
JP2522682B2 (ja) * 1987-12-22 1996-08-07 コニカ株式会社 感度の高いハロゲン化銀写真感光材料
JPH01190798A (ja) * 1988-01-27 1989-07-31 Kao Corp 漂白剤組成物
JP2819415B2 (ja) * 1988-06-03 1998-10-30 富山化学工業株式会社 養毛剤
CH679119A5 (no) * 1988-05-13 1991-12-31 Sandoz Ag
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
JP2857882B2 (ja) * 1988-11-02 1999-02-17 富山化学工業株式会社 ピロキシカムのプラスター剤
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
ATE158950T1 (de) 1989-07-14 1997-10-15 Autoimmune Inc Behandlung der autoimmunen uveoretinitis in menschen
US5194451A (en) * 1989-11-02 1993-03-16 Katz David H Systemic anti-inflammatory treatment
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
JPH03170405A (ja) * 1989-11-29 1991-07-24 Nippon Oil & Fats Co Ltd 魚類の誘引剤
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
MX9301789A (es) 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
JP3211987B2 (ja) * 1992-07-31 2001-09-25 ソニー株式会社 磁気記録媒体
JPH0825857B2 (ja) * 1993-04-28 1996-03-13 株式会社資生堂 アミノ酸長鎖アルキルエステル化タンパクからなる毛髪処理剤
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
JP3413303B2 (ja) * 1995-01-20 2003-06-03 花王株式会社 液体柔軟仕上剤組成物
AU5360796A (en) 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US5945401A (en) 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
TW355153B (en) * 1996-05-21 1999-04-01 Toshiba Machine Co Ltd A method for leveling abrasive cloth and device for the same
EP1001759B1 (en) 1996-09-17 2005-07-20 Avanir Pharmaceuticals Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides
JPH10101630A (ja) * 1996-09-30 1998-04-21 Sankyo Co Ltd 新規化合物Ｂ−５３５４ａ、Ｂ−５３５４ｂ及びＢ−５３５４ｃ
NZ334852A (en) 1996-10-11 2001-05-25 Scotia Holdings Plc Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6210700B1 (en) * 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
US6242426B1 (en) 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
EP0919230A1 (en) * 1997-12-01 1999-06-02 Societe Des Produits Nestle S.A. NMIFA's as anti-inflammatory agents in superficial mammal tissues
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
PL342517A1 (en) 1998-02-23 2001-06-18 Neurocrine Biosciences Methods of treating diabetes employing peptidic insulin analoques
JPH11343235A (ja) 1998-04-02 1999-12-14 Ajinomoto Co Inc アミノ酸誘導体および炎症因子活性化抑制剤
TW544310B (en) * 1998-04-02 2003-08-01 Ajinomoto Kk Amino acid derivatives and anti-inflammatory agents
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
DE19828352A1 (de) * 1998-06-25 1999-12-30 Clariant Gmbh Synergistische Mischungen von Phosphorsäureestern mit Carbonsäuren oder Carbonsäurederivaten als Asphalten-Dispergatoren
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
PT1194109E (pt) 1999-06-25 2004-12-31 Durham Pharmaceuticals Ltd Formulacoes topicas compreendendo agentes de penetracao na pele e utilizacao dasmesmas
JP2002097137A (ja) * 2000-07-19 2002-04-02 Junichi Sudo パーキンソン病の予防および／または治療剤
DE10043196B4 (de) 2000-09-01 2008-10-02 W.C. Heraeus Gmbh Glaskeramikmasse und Verwendung der Glaskeramikmasse
JP4350288B2 (ja) * 2000-09-21 2009-10-21 花王株式会社 ベタインエステルの製造法
GB2393722A (en) * 2001-02-13 2004-04-07 Schlumberger Holdings Cleavable surfactants which may be useful in viscoelastic compositions for oil-field applications
JP2002241317A (ja) * 2001-02-20 2002-08-28 Hirotaka Ihara 光学活性認識剤、それを用いた光学分割カラム充填剤および光学分割方法
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
US6943197B2 (en) * 2002-06-21 2005-09-13 Howard I. Maibach Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses
KR100900448B1 (ko) * 2002-07-09 2009-06-02 엘지전자 주식회사 고밀도 광디스크의 패킷 엔코딩 타임 스탬프 기록방법
EP2117301A4 (en) 2007-02-26 2010-04-14 Yeda Res & Dev USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS
WO2008106092A1 (en) 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses

Also Published As

Publication number Publication date
AU2003269466A1 (en) 2004-05-04
US8987263B2 (en) 2015-03-24
NZ539106A (en) 2007-02-23
RU2337093C2 (ru) 2008-10-27
KR20050071565A (ko) 2005-07-07
CA2501318A1 (en) 2004-04-22
NO20052229L (no) 2005-07-06
BR0314554A (pt) 2005-08-09
IS7781A (is) 2005-03-31
EP1551495A2 (en) 2005-07-13
US20060173053A1 (en) 2006-08-03
CN100582085C (zh) 2010-01-20
WO2004032824A2 (en) 2004-04-22
JP2006502213A (ja) 2006-01-19
RU2005114374A (ru) 2006-02-27
MXPA05003870A (es) 2005-06-22
AU2003269466B2 (en) 2009-08-20
EP1551495A4 (en) 2010-06-02
WO2004032824A3 (en) 2004-08-26
ZA200502613B (en) 2006-10-25
CN1703394A (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
NO20052229D0 (no) Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler
NO20072964L (no) Fremgangsmåte for fremstilling av trans-(-)-¿9-tetrahydrocannabinolsammensetning eller en trans-(+)-¿9-tetrahydrokannabinolsammensetning samt fremgangsmåte for fremstilling av krystallinsk (±)-¿9-tetrahydrokannabinol
MX2008006597A (es) Composiciones de edulcorante de alta potencia con acido graso y composiciones edulcoradas con la misma
IS8233A (is) Própíónsýruafleiður sem eru gagnlegar í meðhöndlun á fitusjúkdómum
NO20054969D0 (no) 2-cyanopropansyreamid- og esterderivater og deres anvendelse
IS2914B (is) Kínólín afleiður og notkun þeirra sem tálma sveppagerla
NO20043004L (no) 4-oksokinolin forbindelse og anvendelse derav som HIV-integraseinhibitor
DE112005003338B8 (de) Niederdruck-Entfernung von Photoresist und Ätzresten
NO20041872L (no) Esterforbindelser og medisinsk anvendelse derav
DE60210512D1 (de) Senkrecht startendes und landendes flugzeug
DK1523532T3 (da) Anti-icing and deicing compositions and method of their application
DE602005015486D1 (de) Esterderivate von ascorbinsäure und 2-ketosäuresacchariden
IS2421B (is) Nýir etónógestrel esterar
DK1763559T3 (da) Höjkoncentrerede vandige formuleringer af oligo- og polyestere
AU2003301240A1 (en) Skin cleanser compositions and methods of use
NO20025307L (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose
ITMI20030541A1 (it) Apparecchio per la caratterizzazione di lesioni pigmentale della cute
IL162937A0 (en) Pravastatin pharmaceutical formulations and methods of their use
ATE439362T1 (de) Ester in position 20 von camptothecinen
FI20021196A (fi) Menetelmä luodin laajentamiseksi ja luoti
JP2003119489A5 (ja) 香料成分としての第三アルコールまたはエステルの使用
ITMI20062227A1 (it) Composizioni gieniche e cosmetiche per il trattamento delle pelli sensibili
IS7537A (is) Notkun á nýjum etónógestrel esterum.
DE502004001936D1 (de) Herstellung von Saccharidestern
AU2003291634A8 (en) Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application